Kromek Group puts front foot forward ahead of CMD

Kromek Group PLC (AIM:KMK) reaffirmed its FY 2025 revenue expectations of at least £26 million, representing a 34% year-on-year increase, driven by its partnership with Siemens Healthineers. Ahead of its Capital Markets Day, the company reiterated its medium-term revenue target of over £60 million with a 30% EBITDA margin. In FY 2024, Advanced Imaging and CBRN Detection generated £9 million and £10.4 million in revenue, respectively, contributing to a total group revenue of £19.4 million.

Analysis

Kromek Group PLC has proactively reiterated its financial guidance ahead of its Capital Markets Day, signaling confidence in its growth trajectory. The company anticipates FY 2025 revenue to surpass market expectations, projecting a figure of not less than £26 million, which translates to a significant year-on-year growth of at least 34%. This robust performance is primarily attributed to its strategic partnership with Siemens Healthineers. For context, Kromek reported total group revenue of £19.4 million in FY 2024, with its Advanced Imaging unit contributing £9 million and the CBRN Detection business £10.4 million. Looking further ahead, Kromek maintains ambitious medium-term targets, aiming for revenue exceeding £60 million and an EBITDA margin of 30%. While no new material information was disclosed in the pre-CMD statement, the reaffirmation of these strong outlook figures underscores the company's positive operational momentum and strategic direction.

Key Decisions for Investors

• Investors should note the reaffirmed strong revenue growth guidance for FY 2025 and the ambitious medium-term financial targets, which signal significant expansion potential.
• The critical dependence on the Siemens Healthineers partnership for driving current growth warrants close monitoring for sustained success and potential risks.
• Future company communications should be scrutinized for tangible progress towards the £26 million FY25 revenue, the medium-term £60 million revenue goal, and the targeted 30% EBITDA margin, as execution against these figures will be key.
• Given the reiteration of existing information, investors should assess if the current valuation adequately reflects these growth prospects and monitor for any further strategic details emerging from the Capital Markets Day.